ACTUALIDADES EN EM

Alvarenga_et_al-2021-Scientific_Reports

Jan 2021 - MSIF Global advice on COVID-19 for people with MS v3 clean

Jamaneurology_de_meo_2021

Articulo publicado en MS and related disordersmain

SEN-Actitudes terapAÞuticas hacia EM CAC frente a SARS-CoV-2-NeurologAÞ-a 2020-S0213485320302371

Guias Consenso CAC

IST during the COVID-19 pandemic in NMOSD_

AQP4 Serostatus and Visual Outcomes JNO 2018

Late-onset NMOSD in LATAM J Nerol 2020

LATAM consensus recomendations for NMOSD

MS and NMOSD in Argentina REeevarEM 2020

Age at onset and disability in NMOSD MSARD 2020

MRI features to distinguish MS from NMOSD MSJ 2019

Management of MS and NMOSD in LATAM during the COVID-19

LATAM consensus recomendations for NMOSD

Rivera 2019 Article Biosimilar Drugs For Multiple Sclerosis

2019 Neurol Ther biosimilars

Introducing iWiMS

Central_Nervous_System_Idiopathic_Inflam

Consenso Terapeutico LACTRIMS

El LCR en las enfermedades desmielinizantes 2012

MS GLOBAL DISEASE TREATMENT ERA biomedicines

SINOPSIS Estudio de prevalencia de esclerosis multiple en el Perú

The genetics of multiple sclerosis in Latin America

Ethical use of off-label disease-modifying

Status of NMOSD in Latam MSARD 6 21

Encuesta 23 JUNIO EM_COVID

IMSB Annual meeting slides 2020

October 2021 - MSIF Global advice on COVID-19 for people with MS v1

Pathways to Cures manuscript 080421

Regina el al 2015

Research Priorities

Lactrims © 2015. Todos los Derechos Reservados